Cargando…
What if HIV were unable to develop resistance against a new therapeutic agent?
BACKGROUND: The HIV integrase inhibitor, Dolutegravir (DTG), was recently approved by the Food and Drug Administration in the United States and is the only HIV drug that has not selected for resistance mutations in the clinic when used as part of first-line therapy. This has led to speculation that...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842747/ https://www.ncbi.nlm.nih.gov/pubmed/24267867 http://dx.doi.org/10.1186/1741-7015-11-249 |